journal

Lancet

journal
https://read.qxmd.com/read/31703957/protecting-the-health-of-children-moving-to-canada
#1
LETTER
Taj Jadavji, Raynell Lang, M John Gill
No abstract text is available yet for this article.
November 5, 2019: Lancet
https://read.qxmd.com/read/31699402/ai-augmented-multidisciplinary-teams-hype-or-hope
#2
LETTER
Antonio Di Ieva
No abstract text is available yet for this article.
November 4, 2019: Lancet
https://read.qxmd.com/read/31685260/chile-civil-unrest-and-cochrane-colloquium-cancelled
#3
LETTER
Erik von Elm, Eva Madrid, Gerard Urrútia
No abstract text is available yet for this article.
November 1, 2019: Lancet
https://read.qxmd.com/read/31679948/pd-1-immunotherapy-for-recurrent-or-metastatic-hnscc
#4
Robert L Ferris, Lisa Licitra
No abstract text is available yet for this article.
October 31, 2019: Lancet
https://read.qxmd.com/read/31679945/pembrolizumab-alone-or-with-chemotherapy-versus-cetuximab-with-chemotherapy-for-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-keynote-048-a-randomised-open-label-phase-3-study
#5
Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G M Hughes, Ricard Mesía, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey-Long Hong, René González Mendoza, Ananya Roy, Yayan Zhang, Burak Gumuscu, Jonathan D Cheng, Fan Jin, Danny Rischin
BACKGROUND: Pembrolizumab is active in head and neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improved response. METHODS: KEYNOTE-048 was a randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries. Participants were stratified by PD-L1 expression, p16 status, and performance status and randomly allocated (1:1:1) to pembrolizumab alone, pembrolizumab plus a platinum and 5-fluorouracil (pembrolizumab with chemotherapy), or cetuximab plus a platinum and 5-fluorouracil (cetuximab with chemotherapy)...
October 31, 2019: Lancet
https://read.qxmd.com/read/31679944/online-education-opportunity-for-syria-s-future-doctors
#6
LETTER
Lamia Kouba, Basel Amin, Amin Azzam
No abstract text is available yet for this article.
October 31, 2019: Lancet
https://read.qxmd.com/read/31679947/entering-the-era-of-highly-effective-cftr-modulator-therapy
#7
Edith T Zemanick, Frank J Accurso
No abstract text is available yet for this article.
October 30, 2019: Lancet
https://read.qxmd.com/read/31679946/efficacy-and-safety-of-the-elexacaftor-plus-tezacaftor-plus-ivacaftor-combination-regimen-in-people-with-cystic-fibrosis-homozygous-for-the-f508del-mutation-a-double-blind-randomised-phase-3-trial
#8
Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people with cystic fibrosis homozygous for the F508del mutation. The addition of elexacaftor (VX-445), a next-generation CFTR corrector, to tezacaftor plus ivacaftor further improved F508del-CFTR function and clinical outcomes in a phase 2 study in people with cystic fibrosis homozygous for the F508del mutation...
October 30, 2019: Lancet
https://read.qxmd.com/read/31677723/sustainable-development-levers-are-key-in-global-response-to-antimicrobial-resistance
#9
Angelina Taylor, Jasper Littmann, Anna Holzscheiter, Maike Voss, Lothar Wieler, Tim Eckmanns
No abstract text is available yet for this article.
October 30, 2019: Lancet
https://read.qxmd.com/read/31676109/department-of-error
#10
(no author information available yet)
No abstract text is available yet for this article.
October 29, 2019: Lancet
https://read.qxmd.com/read/31676108/the-ethics-of-the-global-kidney-exchange-programme
#11
REVIEW
Francesca Minerva, Julian Savulescu, Peter Singer
The Global Kidney Exchange (GKE) programme seeks to facilitate kidney transplants by matching donor-recipient pairs across high-income, medium-income, and low-income countries. The GKE programme pays the medical expenses of people in medium-income and low-income countries, thus enabling them to receive a kidney transplantation they otherwise could not afford. In doing so, the programme increases the global donor pool, and so benefits people in high-income countries by improving their chances of finding a donor match...
October 29, 2019: Lancet
https://read.qxmd.com/read/31668728/a-comprehensive-analysis-of-mortality-related-health-metrics-associated-with-mental-disorders-a-nationwide-register-based-cohort-study
#12
Oleguer Plana-Ripoll, Carsten Bøcker Pedersen, Esben Agerbo, Yan Holtz, Annette Erlangsen, Vladimir Canudas-Romo, Per Kragh Andersen, Fiona J Charlson, Maria K Christensen, Holly E Erskine, Alize J Ferrari, Kim Moesgaard Iburg, Natalie Momen, Preben Bo Mortensen, Merete Nordentoft, Damian F Santomauro, James G Scott, Harvey A Whiteford, Nanna Weye, John J McGrath, Thomas M Laursen
BACKGROUND: Systematic reviews have consistently shown that individuals with mental disorders have an increased risk of premature mortality. Traditionally, this evidence has been based on relative risks or crude estimates of reduced life expectancy. The aim of this study was to compile a comprehensive analysis of mortality-related health metrics associated with mental disorders, including sex-specific and age-specific mortality rate ratios (MRRs) and life-years lost (LYLs), a measure that takes into account age of onset of the disorder...
October 24, 2019: Lancet
https://read.qxmd.com/read/31668727/reduce-the-delay-in-tuberculosis-diagnosis-in-india
#13
LETTER
Sougat Ray, Kavita Anand
No abstract text is available yet for this article.
October 24, 2019: Lancet
https://read.qxmd.com/read/31668726/comprehensive-comparative-effectiveness-and-safety-of-first-line-antihypertensive-drug-classes-a-systematic-multinational-large-scale-analysis
#14
Marc A Suchard, Martijn J Schuemie, Harlan M Krumholz, Seng Chan You, RuiJun Chen, Nicole Pratt, Christian G Reich, Jon Duke, David Madigan, George Hripcsak, Patrick B Ryan
BACKGROUND: Uncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid indications. Randomised trials have not further refined this choice. METHODS: We developed a comprehensive framework for real-world evidence that enables comparative effectiveness and safety evaluation across many drugs and outcomes from observational data encompassing millions of patients, while minimising inherent bias...
October 24, 2019: Lancet
https://read.qxmd.com/read/31668725/what-is-the-first-choice-for-blood-pressure-treatment
#15
Christopher W Ives, Suzanne Oparil
No abstract text is available yet for this article.
October 24, 2019: Lancet
https://read.qxmd.com/read/31668724/premature-mortality-causes-of-death-and-mental-disorders
#16
Kristina Adorjan, Peter Falkai
No abstract text is available yet for this article.
October 24, 2019: Lancet
https://read.qxmd.com/read/31668411/targeting-calcitonin-gene-related-peptide-a-new-era-in-migraine-therapy
#17
REVIEW
Andrew Charles, Patricia Pozo-Rosich
Migraine is one of the most prevalent and disabling diseases worldwide, but until recently, few migraine-specific therapies had been developed. Extensive basic and clinical scientific investigation has provided strong evidence that the neuropeptide calcitonin gene-related peptide (CGRP) has a key role in migraine. This evidence led to the development of small molecule CGRP receptor antagonists and monoclonal antibodies targeting either CGRP or its receptor. Clinical trials investigating these therapies have consistently shown statistically significant efficacy for either the acute or preventive treatment of migraine...
October 23, 2019: Lancet
https://read.qxmd.com/read/31668410/new-psychoactive-substances-challenges-for-drug-surveillance-control-and-public-health-responses
#18
REVIEW
Amy Peacock, Raimondo Bruno, Natasa Gisev, Louisa Degenhardt, Wayne Hall, Roumen Sedefov, Jason White, Kevin V Thomas, Michael Farrell, Paul Griffiths
The rapid emergence since the mid-2000s of a large and diverse range of substances originally designed as legal alternatives to more established illicit drugs (pragmatically clustered and termed new psychoactive substances; [NPS]) has challenged traditional approaches to drug monitoring, surveillance, control, and public health responses. In this section of the Series, we describe the emergence of NPS and consider opportunities for strengthening the detection, identification, and responses to future substances of concern...
October 21, 2019: Lancet
https://read.qxmd.com/read/31668409/responding-to-global-stimulant-use-challenges-and-opportunities
#19
REVIEW
Michael Farrell, Natasha K Martin, Emily Stockings, Annick Bórquez, Javier A Cepeda, Louisa Degenhardt, Robert Ali, Lucy Thi Tran, Jürgen Rehm, Marta Torrens, Steve Shoptaw, Rebecca McKetin
We did a global review to synthesise data on the prevalence, harms, and interventions for stimulant use, focusing specifically on the use of cocaine and amphetamines. Modelling estimated the effect of cocaine and amphetamine use on mortality, suicidality, and blood borne virus incidence. The estimated global prevalence of cocaine use was 0·4% and amphetamine use was 0·7%, with dependence affecting 16% of people who used cocaine and 11% of those who used amphetamine. Stimulant use was associated with elevated mortality, increased incidence of HIV and hepatitis C infection, poor mental health (suicidality, psychosis, depression, and violence), and increased risk of cardiovascular events...
October 21, 2019: Lancet
https://read.qxmd.com/read/31645289/deep-anaesthesia-and-poor-outcomes-the-jury-is-still-out
#20
Helen F Galley, Nigel R Webster
No abstract text is available yet for this article.
October 18, 2019: Lancet
journal
journal
20186
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"